Join the Obinutuzumab group to help and get support from people like you.
Obinutuzumab News
Obinutuzumab Preserves Kidney Function in Lupus Nephritis
THURSDAY, Nov. 16, 2023 – For patients with lupus nephritis (LN), obinutuzumab treatment results in better preservation of kidney function and prevention of LN flares, according to a study published...
FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in...
FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in...
FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
South San Francisco, CA – November 16, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Gazyva...
FDA Approves Genentech’s Gazyva (obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma
South San Francisco, CA – February 26, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Gazyva...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL)